Anika Therapeutics adds two directors, announces $40M buyback under Caligan deal

Anika Therapeutics, Inc.

Appointed Joseph Capper (MIMEDX CEO) and William Jellison (former Stryker CFO) to Board; board expands to 10 then reduces to 9 after 2024 annual meeting.
Authorized $40M share repurchase program: $15M via 10b5-1 by June 2025, remainder open market through June 2026, replacing April 2023 program.
Caligan agrees to standstill, voting commitments, and other provisions under cooperation agreement.
Reaffirmed 2024 adjusted EBITDA guidance of $25-30M, up >75% YoY at midpoint.
New directors join Capital Allocation Committee; no prior relationships or transactions disclosed.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Jellison

Director

ANIK · Anika Therapeutics, Inc.

Effective: 2024-05-28
Filed: May 28, 2024, 7:59 PM ET

the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.

Appointed

Joseph Capper

Director

ANIK · Anika Therapeutics, Inc.

Effective: 2024-05-28
Filed: May 28, 2024, 7:59 PM ET

the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Jellison was appointed as Director at Anika Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Capper was appointed as Director at Anika Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.

View on SEC.gov

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-003136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.